A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma

BACKGROUND: This phase I/II study was conducted to determine the maximum tolerated dose (MTD), safety, and efficacy of lenalidomide plus sunitinib in metastatic renal cell carcinoma (RCC) patients. PATIENTS AND METHODS: Patients with histologically confirmed, metastatic RCC were treated with 10 mg/d...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Oncol
Asıl Yazarlar: Rini, B., Redman, B., Garcia, J. A., Burris, H. A., Li, S., Fandi, A., Beck, R., Jungnelius, U., Infante, J. R.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2014
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4311191/
https://ncbi.nlm.nih.gov/pubmed/24914044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdu212
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller